Moulton D, Raj K. Demethylation agents – do they have a future? MDIP 2008; 2(3): 7

Myeloproliferative Disorders in practice

Reference list

Moulton D, Raj K. Demethylation agents – do they have a future? MDIP 2008; 2(3): 7–9.

1. Piskala A, Sorm F. Nucleic acids components and their analogues. LI. Synthesis of 1-glycosyl derivatives of 5-azauracil and 5-azacytosine. Coll Czeck Chem Commun 1964; 29: 2060–2076.

2. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980; 20: 85–93.

3. Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1986; 321: 209–213.

4. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042–2054.

5. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61: 3225–3229.

6. Herman JG, Civin CI, Issa JP et al. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 1997; 57: 837–841.

7. Quesnel B, Guillerm G, Vereecque R et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998; 91: 2985–2990.

8. National Cancer Institute. Press release: FDA Approval for Decitabine. www.cancer.gov/cancertopics/druginfo/fda-decitabine (last accessed 28 July 2008)

9. Christman JK. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002; 21: 5483–5495.

10. Von Hoff DD, Slavik M, Muggia FM. 5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia. Ann Intern Med 1976; 85: 237–245.

11. Karon M, Sieger L, Leimbrock S et al. 5-Azacytidine: a new active agent for the treatment of acute leukemia. Blood 1973; 42: 359–365.

12. Vogler WR, Miller DS, Keller JW. 5-Azacytidine (NSC 102816): a new drug for the treatment of myeloblastic leukemia. Blood 1976; 48: 331–337.

13. Silverman L, Holland JF, Demakos EP et al. Azacytidine in myelodysplastic syndromes: CALGB studies 8421 and 8921. Ann Hematol 1994; 68(Suppl 2): Abstract 12.

14. Aribi A, Borthakur G, Ravandi F et al. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer 2007; 109: 713–717.

15. Fenaux P, Mufti GJ, Santini V et al. Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study. Blood (ASH Annual Meeting Abstracts) 2007; 110: Abstract 817.

16. Kantarjian H, Issa JP, Rosenfeld CS et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794–1803.

17. Kantarjian H, Oki Y, Garcia-Manero G et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109: 52–57.

18. Mesa RA, Verstovsek S, Rivera C et al. 5-Azacitidine has limited therapeutic activity in myelofibrosis. Leukemia 2008: Epub before print.

19. Oki Y, Kantarjian HM, Gharibyan V et al. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer 2007; 109: 899–906.

20. Quintas-Cardama A, Tong W, Kantarjian H et al. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia 2008; 22: 965–970.

21. Silverman LR, Demakos EP, Peterson BL et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429–2940.

22. Wijermans PW, Lubbert M, Verhoef G, Klimek V, Bosly A. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients. Ann Hematol 2005; 84(Suppl 1): 9–17.

23. Raj K, John A, Ho A et al. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia 2007; 21: 1937–1944.

24. List AF, Fenaux P, Mufti GM et al. Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission. J Clin Oncol 2008; 26(Suppl): Abstract 7006.

25. Silverman LR, McKenzie DR, Peterson BL et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006; 24: 3895–3903.

26. Craddock C. Personal Communication, 2008. Birmingham.

27. Kantarjian HM, O'Brien S, Cortes J et al. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 2003; 98: 522–528.

28. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21: 103–107.

29. Gore SD, Baylin S, Sugar E et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006; 66: 6361–6369.

30. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 2006; 108: 3271–3279.

31. Gollob JA, Sciambi CJ, Peterson BL et al. Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin Cancer Res 2006; 12: 4619–4627.

32. Plimack ER, Stewart DJ, Issa JP. Combining epigenetic and cytotoxic therapy in the treatment of solid tumors. J Clin Oncol 2007; 25: 4519–4521.

33. Saunthararajah Y, Molokie R, Saraf S et al. Clinical effectiveness of decitabine in severe sickle cell disease. Br J Haematol 2008; 141: 126–129.

Published by Hayward Medical Communications